Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Sage Therapeutics, Inc.    SAGE

SAGE THERAPEUTICS, INC.

(SAGE)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/15/2021 01/19/2021 01/20/2021 01/21/2021 01/22/2021 Date
91.38(c) 89.55(c) 91.21(c) 92.44(c) 88.55(c) Last
572 326 473 881 368 702 380 028 497 816 Volume
-5.56% -2.00% +1.85% +1.35% -4.21% Change
More quotes
Financials (USD)
Sales 2020 7,04 M - -
Net income 2020 -473 M - -
Net cash position 2020 1 245 M - -
P/E ratio 2020 -9,76x
Yield 2020 -
Sales 2021 238 M - -
Net income 2021 -153 M - -
Net cash position 2021 1 745 M - -
P/E ratio 2021 -31,9x
Yield 2021 -
Capitalization 5 161 M 5 161 M -
EV / Sales 2020 556x
EV / Sales 2021 14,4x
Nbr of Employees 675
Free-Float 87,7%
More Financials
Company
SAGE Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company's lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor. The Company's... 
More about the company
Notations Surperformance© of Sage Therapeutics, Inc.
Trading Rating : Investor Rating :
More Ratings
All news about SAGE THERAPEUTICS, INC.
01/22SAGE THERAPEUTICS : BMO Capital Downgrades Sage Therapeutics to Market Perform F..
MT
01/22PRESS RELEASE : BB BIOTECH AG: Vaccines leading -2-
DJ
01/19SAGE THERAPEUTICS : Wedbush Adjusts Price Target on Sage Therapeutics to $98 Fro..
MT
01/07SAGE THERAPEUTICS, INC. : Results of Operations and Financial Condition, Other E..
AQ
01/07SAGE THERAPEUTICS : Provides 2021 Corporate Strategy Update at J.P. Morgan Healt..
BU
01/04SAGE THERAPEUTICS : Guggenheim Upgrades Sage Therapeutics to Buy From Neutral, S..
MT
01/04SAGE THERAPEUTICS : RBC Downgrades Sage Therapeutics to Sector Perform From Outp..
MT
2020SAGE THERAPEUTICS, INC. : Other Events (form 8-K)
AQ
2020SAGE THERAPEUTICS : to Present at the 39th Annual J.P. Morgan Healthcare Confere..
BU
2020SAGE THERAPEUTICS : Names Barry Greene CEO
MT
2020SAGE THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
2020SAGE THERAPEUTICS : Announces the Appointment of Barry Greene as CEO
BU
2020Mizuho Upgrades Sage Therapeutics to Buy From Neutral, Adjusts Price Target t..
MT
2020SAGE THERAPEUTICS : to Present at BMO 2020 Growth and ESG Conference
AQ
2020SAGE THERAPEUTICS : to Present at BMO 2020 Growth & ESG Conference
BU
More news
News in other languages on SAGE THERAPEUTICS, INC.
2019Wall Street finit en hausse après une séance hésitante
2019SAGE THERAPEUTICS, INC. : massacre en vue à Wall Street
2019AVIS D'ANALYSTES DU JOUR : Air France, BNP Paribas, Teleperformance, DBV Technol..
2019STOCK MARKET PARIS : La Fed choisit la sobriété
2019STOCK MARKET PARIS : Et si l'Allemagne aidait la BCE à relancer la croissance ?
More news
Analyst Recommendations on SAGE THERAPEUTICS, INC.
More recommendations
Chart SAGE THERAPEUTICS, INC.
Duration : Period :
Sage Therapeutics, Inc. Technical Analysis Chart | SAGE | US78667J1088 | MarketScreener
Technical analysis trends SAGE THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 99,30 $
Last Close Price 88,55 $
Spread / Highest target 113%
Spread / Average Target 12,1%
Spread / Lowest Target -20,9%
EPS Revisions
Managers and Directors
NameTitle
Barry E. Greene President, Chief Executive Officer & Director
Kevin Paul Starr Chairman
Michael Cloonan Chief Operating Officer
Kimi E. Iguchi Chief Financial Officer & Treasurer
Albert J. Robichaud Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
SAGE THERAPEUTICS, INC.2.36%5 161
MODERNA, INC.25.41%52 622
LONZA GROUP AG4.64%49 880
CELLTRION, INC.-13.65%38 701
IQVIA HOLDINGS INC.3.58%35 985
SEAGEN INC.4.35%33 607